Filtered By:
Education: Study
Vaccination: Vaccines
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 443 results found since Jan 2013.
ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also suppor...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Neurological symptoms and neuroimaging alterations related with COVID-19 vaccine: Cause or coincidence?
Although vaccination against Coronavirus disease-2019 (COVID-19) is still occurring, several adverse effects temporally related to these vaccines are already being reported, even if through isolated case reports. In the present study, we describe the lesions seen on magnetic resonance imaging (MRI) of three patients who developed neurological symptoms after receiving the ChAdOX1 nCoV-19 vaccine (Oxford/AstraZeneca). The first patient presented with an ischemic stroke in the posterior limb of the left internal capsule, two days after vaccination.
Source: Clinical Imaging - September 6, 2021 Category: Radiology Authors: Diogo Goulart Corr êa, Luis Alcides Quevedo Cañete, Gutemberg Augusto Cruz dos Santos, Romulo Varella de Oliveira, Carlos Otávio Brandão, Luiz Celso Hygino da Cruz Tags: Neuroradiology Source Type: research
Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature
ConclusionTo our knowledge, this is the one of early reported case of transverse myelitis and with post SARS-CoV-2 vaccination, who responded well to plasmapheresis. Further studies would be recommended to identify the underlying correlation between COVID-19 vaccination and transverse myelitis.
Source: Journal of Neurology - September 5, 2021 Category: Neurology Source Type: research
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,” sai...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Pfizer vaccine: BMJ study finds risk of a serious complication '15 to 21 days' after jab
A NEW large-scale study has pitted the risks posed by the AstraZeneca and Pfizer vaccines against the risks posed from COVID-19. Among the key findings was an increased risk of stroke following the Pfizer jab, but the risk remains 10 times greater in those with COVID-19.
Source: Daily Express - Health - August 27, 2021 Category: Consumer Health News Source Type: news
Covid Infection Has ‘Much Higher’ Risk Of Blood Clots Than Vaccines Do, Study Finds
While there is an increased risk of stroke after the first Pfizer shot and a higher change of blood clotting following AstraZeneca, a Covid-19 infection comes with at least ten times higher risk, research found.
Source: Forbes.com Healthcare News - August 27, 2021 Category: Pharmaceuticals Authors: Robert Hart, Forbes Staff Tags: Business /business Innovation /innovation Healthcare /healthcare Breaking breaking-news Editors' Pick editors-pick Coronavirus Source Type: news
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Acute prolonged motor aura resembling ischemic stroke after COVID − 19 vaccination (CoronaVac): the first case report
In this study, we present the first case of stroke mimic after CoronaVac vaccination. After negative imaging studies had been performed repeatedly, we reach a conclusion that stroke is unlikely to be the cause. Presumably, this phenomenon could possibly have abnormal functional imaging study. Therefore, we believed that it might be due to cortical spreading depression, like migraine aura, which we had conducted a literature review.
Source: The Journal of Headache and Pain - August 12, 2021 Category: Neurology Source Type: research
COVID-19 Infection: A Neuropsychiatric Perspective
J Neuropsychiatry Clin Neurosci. 2021 Jul 19:appineuropsych20110277. doi: 10.1176/appi.neuropsych.20110277. Online ahead of print.ABSTRACTAs a potentially life-threatening disease with no definitive treatment and without fully implemented population-wide vaccination, COVID-19 has created unprecedented turmoil in socioeconomic life worldwide. In addition to physical signs from the respiratory and many other systems, the SARS-CoV-2 virus produces a broad range of neurological and neuropsychiatric problems, including olfactory and gustatory impairments, encephalopathy and delirium, stroke and neuromuscular complications, stre...
Source: Journal of Neuropsychiatry and Clinical Neurosciences - July 19, 2021 Category: Psychiatry Authors: Theodora A Manolis Evdoxia J Apostolopoulos Antonis A Manolis Helen Melita Antonis S Manolis Source Type: research
Flu vaccine protects against severe effects of COVID-19, according to new study
THE FLU vaccine may provide vital protection against COVID-19, according to new research. The annual flu shot was found to reduce the risk of stroke, sepsis and DVT in patients with the virus.
Source: Daily Express - Health - July 12, 2021 Category: Consumer Health News Source Type: news
Flu jab may reduce severe effects of Covid, suggests study
Analysis of 75,000 coronavirus patients found fewer major health problems among people with flu jabCoronavirus – latest updatesSee all our coronavirus coveragePeople who are vaccinated against influenza may be partly protected against some of the severe effects of coronavirus, and be less likely to need emergency care, according to a major study.The analysis of nearly 75,000 Covid patients found significant reductions in stroke, deep vein thrombosis (DVT) and sepsis, and fewer admissions to emergency departments and intensive care units, among those who had been given the flu jab.Continue reading...
Source: Guardian Unlimited Science - July 12, 2021 Category: Science Authors: Ian Sample Science editor Tags: Medical research Coronavirus Vaccines and immunisation Health UK news Source Type: news
